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Abstract
Background: In spite of bearing a heavier burden of death, disease and disability, there is mixed evidence as to
whether Indigenous Australians utilise more or less healthcare services than other Australians given their
elevated risk level. This study analyses the Medicare expenditure and its predictors in a cohort of Indigenous
and non-Indigenous Australians at high risk of cardiovascular disease.
Methods: The healthcare expenditure of participants of the Kanyini Guidelines Adherence with the Polypill (GAP)
pragmatic randomised controlled trial was modelled using linear regression methods. 535 adult (48% Indigenous)
participants at high risk of cardiovascular disease (CVD) were recruited through 33 primary healthcare services
(including 12 Aboriginal Medical Services) across Australia.
Results: There was no significant difference in the expenditure of Indigenous and non-Indigenous participants in
non-remote areas following adjustment for individual characteristics. Indigenous individuals living in remote
areas had lower MBS expenditure ($932 per year P < 0.001) than other individuals. MBS expenditure was found to
increase with being aged over 65 years ($128, p = 0.013), being female ($472, p = 0.003), lower baseline reported
quality of life ($102 per 0.1 decrement of utility p = 0.004) and a history of diabetes ($324, p = 0.001), gout ($631,
p = 0.022), chronic obstructive pulmonary disease ($469, p = 0.019) and established CVD whether receiving
guideline-recommended treatment prior to the trial ($452, p = 0.005) or not ($483, p = 0.04). When controlling for all
other characteristics, morbidly obese patients had lower MBS expenditure than other individuals (−$887, p = 0.002).
Conclusion: The findings suggest that for the majority of participants, once individuals are engaged with a primary
care provider, factors other than whether they are Indigenous determine the level of Medicare expenditure for each
person.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN 126080005833347.
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Background
The burden of chronic diseases facing Australians has
grown significantly over recent decades making providing
appropriate care for these patients increasingly complex
[1, 2]. Studies have shown a growing burden on health sys-
tem expenditure in Australia as a result of the increased
prevalence of obesity and diabetes for example [3], while
other chronic diseases such as chronic obstructive pul-
monary disease (COPD), gout and cardiovascular diseases
(CVD) are likely to place significant demands on health
system resources.
Greater chronic disease multi-morbidity is an import-
ant contributor to the health gap between Aboriginal
and Torres Strait Islander (Indigenous) Australians and
non-Indigenous Australians [4]. Ensuring that Indigen-
ous Australians have access to effective healthcare ser-
vices is a central component of government attempts to
eradicate these inequalities [5]. Nonetheless, a number
of barriers prevent Indigenous Australians from accessing
appropriate health services including financial, cultural,
geographic and health-literacy impediments [6, 7].
Healthcare service use of indigenous Australians
Without controlling for the relative need of the two
groups, the average public spend on healthcare for an
Indigenous Australian is estimated at $1.47 for every $1
spent for the care of a non-Indigenous Australian [8].
The distribution of this spend differs markedly between
the two groups, however, with Indigenous Australians
utilising significantly less Medicare Benefit Schedule
(MBS) and medication expenditure (at a rate of 0.63 and
0.44 respectively) than other Australians but having
much higher average hospital expenditure (1.76 times
higher than non-Indigenous Australians). MBS expend-
iture incorporates general practitioner and specialist
visits and diagnostic tests. Given the substantial dispar-
ities in health outcomes facing Indigenous Australians,
many have questioned whether the expenditure on Indi-
genous individuals, in particular for primary healthcare,
should be higher relative to non-Indigenous Australians
[6, 9]. Limited research has been able to effectively ad-
just for the different clinical risk profiles of the two pop-
ulations. One study that was able to do so (through
controlling for self-reported indicators of ill health)
found that Indigenous Australians used more healthcare
services than other Australians [10].
This study investigates these issues using patient-level
clinical data to examine the relative patterns of health-
care expenditure of Indigenous and non-Indigenous
individuals at high-risk of CVD and investigate the
predictors of expenditure across the two groups. Un-
derstanding the healthcare utilisation patterns of these
populations is important to ensure that the health system
is providing the level of care required to close the gap in
health outcomes between Indigenous and non-Indigenous




Data were collected during the Kanyini Guidelines Ad-
herence with the Polypill (GAP) randomised controlled
trial testing the effectiveness of a cardiovascular combin-
ation polypill (containing aspirin, simvastatin and two
low dose blood pressure lowering agents) in Indigenous
and non-Indigenous adults over 18 years at high-risk of
CVD. High-risk of CVD was defined as either an estab-
lished diagnosis of CVD or an estimated five-year risk of
CVD greater than 15 percent based on the Framingham
risk equation (with an additional five percent increment
for Indigenous participants) [11]. Participants were ex-
cluded if it was deemed clinically inappropriate to alter
their medications. Participants had a median follow-up
of 19 months (maximum follow up of 36 months). Fur-
ther details of the trial design and randomisation
process are presented elsewhere [11]. The trial was ap-
proved by human research ethics committees in all
relevant jurisdictions.
Service expenditure
Data collected included data from the Medicare Benefits
Schedule (MBS), which records government and patient
out of pocket expenditure (government legislated co-
payments) on general practitioner and specialist visits
and diagnostic tests, linked with data from the clinical
trial [12]. MBS data are automatically collected at the
point of service when the healthcare provider bills the
government or patient for the service rendered and par-
ticipants consent for these data to be linked to the data
collected through the trial. Pharmaceutical Benefit
Schedule (PBS) data were also collected for the trial,
however, this did not include: (1) the polypill treatment
used in the trial (as it was not PBS-approved); (2)
pharmaceutical treatments falling under the general co-
payment threshold; and (3) those medicines accessed by
people of remote Aboriginal Health Services under the
provisions of section 100 of the National Health Act
(1953) [13]. As such, the average MBS expenditure per
patient per follow-up year was used as the outcome vari-
able for the analysis.
Geographic setting
The trial was conducted within Indigenous-specific (12
centres) and other primary-care providers (21 centres) in
urban, rural and remote settings around Australia.
Urban, regional or remote areas were classified based on
definitions of the Australian Bureau of Statistics [14]. For
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this analysis, ‘remote’ is used to refer to those living in ei-
ther remote or very remote areas under these definitions.
Statistical analysis
The average annual MBS benefit of the two groups was
modelled using linear regression methods using Stata
13.1 (StataCorp). To account for the skewness of the
data, the outcome variable was log-transformed and
then estimated using linear regression models [15]. The
adjusted log means were then transformed back to a
dollar scale using a smearing estimate in order to de-
rive unbiased estimates of mean costs [16]. Medicare
benefit expenditure was estimated within key socioeco-
nomic and demographic variables collected from study
participants at the baseline visit including gender, income,
whether they received the polypill or usual care, Indigen-
ous status, remoteness, highest education level attained,
the presence of certain chronic diseases (diabetes, COPD,
gout and morbid obesity defined as having a body mass
index (BMI) greater than 40), whether a person was a pri-
mary or secondary prevention patient and whether they
were on appropriate medication prior to entering the trial
with and without covariate adjustments. The quality of life
of the patient measured at baseline using the EQ-5D and
converted to a summary score using Australian based
estimates was included as an explanatory variable in
the analysis [17]. Non-significant baseline covariates
(P > 0.1) were removed via backwards stepwise elimin-
ation. Age of participants and morbid obesity were in-
cluded as dummy variables in the analysis due to an
observed differential impact for those aged 65 years
and over and those with a BMI over 40. Indigenous sta-
tus was captured through two dummy variables, one in-
dicating if they lived in a remote area and another if
they lived in an urban or regional setting. This was ne-
cessary as the impact of living in a rural area could not
be isolated for non-Indigenous Australians as there
were too few non-Indigenous people in the sample liv-
ing in rural or remote locations. All costs are presented
in 2012 Australian dollars.
Results
General characteristics
Complete data were available for 535 participants in the
Kanyini GAP study which represented 88% of the total
trial population1. Table 1 summarises the general charac-
teristics of participants and shows the average MBS ex-
penditure by each category shown. It is important to
highlight that the individual characteristics vary across
the urban and regional Indigenous, Remote Indigenous
and non-Indigenous groups and as such, this average
expenditure should be interpreted with caution. The
sample included 48% Indigenous people, had an average
age of 63 years and 36% were female. Overall, 67% of
participants were from urban areas, 12% from regional
areas and 21% were from remote areas. Thirty-eight per-
cent of the patient cohort were receiving treatment for the
primary prevention of CVD and 62% had an established
diagnosis of CVD prior to entering the study. The average
BMI of participants was 31 with 9.7% (52 participants) of
the cohort classified as morbidly obese. The average five
-year cardiovascular risk score of primary prevention pa-
tients was 18.7%, and this was similar for Indigenous
(18.7%) and non-Indigenous (18.6%) individuals. On aver-
age, Indigenous participants were younger, more likely to
be receiving primary rather than secondary prevention
care and more likely to live in rural or remote locations
than their non-Indigenous counterparts.
There were no major differences between Kanyini
GAP participants who were included and excluded from
this analysis (88 subjects) in terms of age, primary pre-
vention risk score, average age or regional classification.
A higher proportion of trial participants who did not
provide consent for linkage to their MBS records were
Indigenous (64%).
Service utilisation
On average, participants accessed a total of 34 MBS ser-
vices per year during the trial. The average MBS benefit
paid per year for care of the patient cohort was $1,699.
Indigenous participants had lower MBS service utilisa-
tion across the trial (see Table 2). Remote Indigenous
participants had accessed almost 27 MBS services as
opposed to 36 for other participants (Indigenous and
non-Indigenous) and had an average MBS Benefit ex-
penditure of $1,161 compared to $1,843.
Predictors of service expenditure
Table 3 outlines the predicted variation in MBS benefits
based on the model developed. Indigenous patients (liv-
ing in non-remote areas) were estimated to have an
average annual MBS benefit expenditure $108 higher
than non-Indigenous participants, however, this differ-
ence was not statistically significant (p = 0.33). Indigen-
ous people living in remote locations, however, had an
average annual MBS benefit expenditure $932 less than
other participants (p < 0.001). Baseline self-reported
quality of life was significantly associated with the MBS
benefit expenditure of the patients with expenditure in-
creasing on average $102 for each 0.1 decrement of util-
ity. Morbidly obese patients (BMI > 40) had significantly
lower MBS expenditure per year ($887 lower per year,
p = 0.002). Medicare expenditure was significantly associ-
ated with whether a person was a primary or secondary
prevention patient and whether they were on appropriate
medications before they started the trial: secondary
prevention patients who were not on all evidence-based
medications prior to the start of the trial were estimated
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to have service use $483 higher on average than primary
prevention patients who were similarly not on appropriate
medications (p = 0.04). Other socio-demographic variables
including the education level and income of the partici-
pants were not statistically significant predictors of service
use once the other variables were included in the model.
The MBS expenditure of participants was not different
between the randomisation groups, that is, whether they
received the polypill intervention or usual care in the trial.
Discussion
Cardiovascular diseases are estimated to affect 5.2% of
Australians [18], 12% of Indigenous Australians [19] and
have been estimated to be responsible for approximately
Table 1 General Characteristics of Cohort











Participants 535a $1,699 146 (27%) $1,863 113 (21%) $1,161 276 (52%) $1,833
Age, mean (SD) 63 (12.5) NA 57 (8.8) NA 55 (13.6) NA 70 (9.5) NA
Morbidly Obese 52 (10%) $1,310 27 (18%) $1,519 9 (8%) $637 16 (7%) $1,336
Female 193 (36.1%) $1,833 56 (39%) $1,932 49 (43%) $1,284 88 (32%) $2,075
Primary Healthcare Provider
Aboriginal Medical Service (AMS) 266 (50%) $1,580 136 (93%) $1,901 113 (100%) $1,161 17 (6%) $1,805
Non-AMS 269 (50%) $1,816 10 (7%) $1,346 0 (0%) NA 259 (94%) $1,834
Geographical Classification
Urban 356 (67%) $1,878 102 (70%) $1,979 0 (0%) NA 254 (92%) $1,837
Regional 64 (12%) $1,625 44 (30%) $1,594 0 (0%) NA 20 (7%) $1,693
Remote and very Remote 115 (21%) $1,185 0 (0%) NA 113 (100%) $1,161 2 (1%) $2,565
CVD Risk Group
Primary Prevention, not on optimal
therapy before the trial
94 (18%) $1,421 41 (28%) $1,623 20 (18%) $789 33 (12%) $1,421
Primary Prevention, on optimal therapy
before the trial
108 (20%) $1,601 22 (15%) $1,980 39 (35%) $959 47 (17%) $1,957
Secondary Prevention, not on optimal
therapy before the trial
42 (8%) $1,941 12 (8%) $1,819 4 (4%) $1,346 26 (9%) $2,089
Secondary Prevention, on optimal
therapy before the trial
291 (54%) $1,790 71 (49%) $1,973 50 (44%) $1,452 170 (62%) $1,813
Highest Educational Attainment
Primary education or lower 142 (27%) $1,513 51 (35%) $1,703 49 (43%) $1,041 42 (15%) $1,834
Secondary level 247 (46%) $1,742 56 (38%) $1,844 44 (39%) $1,236 147 (53%) $1,855
Post-secondary 146 (27%) $1,807 39 (27%) $2,099 20 (18%) $1,288 87 (32%) $1,795
Risk Score of primary prevention patients,
mean (SD)
18.7 (5.9) NA 19.2 (5.8) NA 18.3 (6.8) NA 18.6 (5.2) NA
Presence of COPD at baseline of trial 45 (8%) $2,130 23 (16%) $2,146 5 (4%) $2,405 17 (6%) $2,027
Presence of diabetes at baseline of trial 289 (54%) $1,741 98 (67%) $1,961 83 (73%) $1,083 108 (39%) $2,047
Presence of gout at baseline of trial 109 (20%) $2,054 30 (21%) $2,139 14 (12%) $1,340 65 (24%) $2,169
Received polypill intervention 272 (51%) $1,708 69 (47%) $2,052 59 (52%) $1,161 144 (52%) $1,766
a88% of Kanyini GAP trial participants
Table 2 Average Selected services per follow-up year
Total Urban and Regional Indigenous Remote Indigenous Non-Indigenous
Number of MBS Services 34 36 27 36
Average Total MBS Benefit Expenditure per year $1,699 $1,863 $1,161 $1,833
Average MBS Out of Pocket Expenditure $67 $16 $4 $121
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a quarter of the gap in health outcomes between Indi-
genous and non-Indigenous Australians [4, 20]. CVD
hospitalisations and death rates in remote and very re-
mote areas of Australia are estimated to be 30% higher
than in major cities [21]. Ensuring that Indigenous and
remote communities experiencing or at risk of CVD can
access appropriate care is vital to closing this gap. This
study provides a unique insight into the service use pat-
terns of this high-risk cohort. Average MBS expenditure
was lower per capita for Indigenous Australians relative
to other participants, in line with national estimates [8].
Most of this difference, however, resulted from remote
Indigenous participants receiving significantly lower levels
of Medicare-funded care. While this finding is consistent
with previous literature highlighting service-gaps and diffi-
culties in providing healthcare services to remote commu-
nities, Medicare services are also an incomplete picture of
healthcare being received as many services may be funded
by other sources including government grants, which pre-
vious estimates have suggested could represent up to
$1,300 per person per year of services in these areas [22].
This would account for a large part of the difference in
Medicare expenditure between remote Indigenous and
other participants found in this study. It is worth noting
though the potential equity implications resulting from a
two-tiered funding system. Most notably, the additional
burden on AMS providers who need to apply for and meet
other requirements of these grants has been well docu-
mented [23, 24].
On the other hand, once demographic and risk-related
factors were controlled for there was no significant dif-
ference in the MBS expenditure of Indigenous and
non-Indigenous participants. For Indigenous individ-
uals living in non-remote locations, other factors were
more important in determining their care than their
Indigeneity. This suggests that this cohort of high-risk
individuals were receiving care equivalent to their non-
Indigenous counterparts with similar risk levels. While
it could be argued that these individuals should be re-
ceiving a greater level of care to ‘close the gap’, this is a
promising result particularly given that almost all Indi-
genous individuals in this cohort received care at an
Aboriginal-specific primary healthcare centre. The im-
portance of Aboriginal-specific services and culturally
appropriate care has been highlighted repeatedly in the
qualitative literature as an essential component in en-
suring that appropriate care is received by these com-
munities [25–28]. The findings of this study suggest
that in urban areas at least, culturally-specific services
can help to overcome the underutilisation of primary
care services by Australia’s Indigenous communities.
Further it suggests that urban Indigenous specific pro-
viders may be overcoming a historical underutilisation
of Medicare as a funding source.
We were unable to separate the MBS expenditure into
that relating to cardiovascular as opposed to other spe-
cialties as the majority of costs were for services such
as pathology tests and general consultations which may
result from a number of conditions. While a patient
history of gout, diabetes and COPD were all associated
with significantly higher Medicare expenditure as would
be expected, morbidly obese patients were found to be re-
ceiving significantly lower levels of care receiving almost
$900 less care per year than other participants and an
average of under 29 services per year as opposed to 34 for
other participants. This goes against findings in the litera-
ture that have found increased levels of obesity to be asso-
ciated with higher expenditure [3] as well as national data
Table 3 Average increases in estimated annual MBS benefit associated with patient characteristics
Increase in estimated annual MBS Benefita p-Value**
Urban Indigenous $108 0.326
Baseline quality of life $102 per 0.1 decrement in utility 0.004
Aged 65 and over $128 0.013
Female $472 0.003
Remote Indigenous -$932 <0.001
Primary prevention and on optimal medications prior to trial $285 0.193
Secondary prevention and not on optimal medications prior to trial $483 0.04
Secondary prevention and on optimal medications prior to trial $452 0.005
Patient history of gout $631 0.022
Patient history of diabetes $324 0.001
Patient history of COPD $469 0.019
BMI > 40 -$887 0.002
Constant $2,379 <0.001
aexpenditure increases based on differences in smeared means
**p-values based on natural log-transformed data adjusted for all variables included above
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indicating that obese people were more likely to see a GP
than non-obese individuals [29]. While the reasons under-
lying this finding are not immediately apparent there are
several potential explanations. First, we did not have data
on the hospital service use of patients so that the differ-
ence in Medicare expenditure may be compensated by
hospital expenditure if these morbidly obese individuals
used more hospital services. Second, previous studies have
not controlled for the presence of multi-morbidities as we
have suggesting that perhaps the higher expenditure found
in those studies may reflect the presence of other chronic
diseases. Third, it may be the case that the morbidly obese
patients are either less proactive in seeking out health
services or the primary healthcare services may not be
meeting the needs of this cohort. Given the increasing
prevalence of obesity in Australia, it is vital to ensure
that primary care providers effectively meet the health-
care needs of this population to maximise patient out-
comes and minimise downstream cost impacts. In any
case, this relationship between service use and obesity
warrants further investigation.
There were several limitations to this analysis. First,
the sample is not representative of the general Austra-
lian Indigenous population. Participants were recruited
from primary care services such that they were already
receiving care and many of the impediments to care dis-
cussed in the literature had already been overcome. This
might lead to our estimates of expenditure being an
overestimate for these communities. Further our focus
on Indigenous communities likely means our cohort is
not generalizable to the broader Australian population
at high-risk of CVD. Second, there were too few non-
Indigenous Australians living in remote locations to sep-
arate the impact of living in a remote area and that of
being Indigenous. While one of the strengths of the
paper was our ability to exploit patient-level data to con-
trol for risk and other socio-demographic variables there
are limitations to the dataset. We did not have access to
hospital data and the lack of clarity around potential al-
ternative services being provided particularly in remote
areas means that we cannot ascertain the exact level of
services being accessed by these communities. Similarly,
other characteristics that we could not control for may
influence the healthcare spend of these individuals. Fi-
nally, our data may be affected by the higher rate of
Indigenous participants who did not consent to link
their trial and Medicare data.
Conclusion
Understanding the healthcare utilisation patterns of In-
digenous Australians is important to ensure that the
health system is providing the level of care required to
close the gap in health outcomes between Indigenous
and non-Indigenous Australians. This analysis suggests
that in an urban setting, once individuals are engaged
with a service, culturally-specific care providers can be
effective in providing care to this high-risk patient
group. Indigenous individuals living in remote areas had
significantly lower levels of Medicare funded care, how-
ever, we were unable to determine if this was a result of
fewer services being received or limitations with our
data. Policy efforts to improve access to primary care for
Indigenous Australians should focus on getting these
communities engaged with care providers and overcom-
ing barriers facing those in remote areas.
Endnotes
1Six hundred twenty-three completed the trial, 555
provided consent for Medicare, complete health related
quality of life data for 535.
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